Peptide · Fact sheet
Tirzepatide
Also known as Mounjaro · Zepbound
Tirzepatide is FDA approved in specific prescription products and populations. Zepbound also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
What is Tirzepatide?
Tirzepatide is a manufactured medicine that activates two receptors involved in metabolic signaling: GIP and GLP-1.
Mounjaro and Zepbound contain the same active ingredient but have distinct FDA-labeled uses.
Benefits people look for
Interest centers on blood-sugar control, body-weight outcomes, and the obstructive-sleep-apnea indication.
It is also being studied for cardiovascular, kidney, and liver outcomes.
What the evidence supports
- Trials supporting approved labels found benefits in their specified metabolic and sleep-apnea outcomes.
- Additional outcome studies may clarify where benefits extend beyond current labels.
All research areas
- Type 2 diabetes
- Chronic weight management
- Obstructive sleep apnea in adults with obesity
- Cardiovascular and kidney outcomes
- Metabolic liver disease
- Additional cardiovascular, kidney, and liver outcomes
- Other uses not listed in a current product label
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Less preoccupation with food
A person describing two weeks with tirzepatide reported less constant thinking about meals and more mental space for work.
This short, enthusiastic account is not a validated measure of cognition or a prediction of longer-term results. Selected public self-report; identity, product contents, other exposures and outcomes were not independently verified. It cannot establish causation or frequency.
Read the personal account ↗Side effects & risks
- Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and other gastrointestinal symptoms.
- Current labeling includes a boxed warning about thyroid C-cell tumors in rats and important contraindications.
- Other labeled concerns include pancreatitis, gallbladder problems, kidney injury, hypoglycemia with certain medicines, and aspiration risk around anesthesia or deep sedation.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesLarge randomized trials support approved indications. Results cannot be assumed to apply to unstudied populations, products, or claims.
Selected research to read
Registry record for a pivotal tirzepatide chronic-weight-management trial.
Peer-reviewed report of tirzepatide in adults with obesity.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| SURMOUNT-1 Adults with obesity or overweight plus a complication; diabetes excluded 2,539 participants (actual) Randomized placebo-controlled trial; human | Tirzepatide versus Placebo 72 weeks Primary: Percentage weight change and proportion reaching at least 5% reduction Phase: Phase 3 | Active groups had greater mean weight reduction than placebo. Cannot tell us: Weight change alone does not quantify cardiovascular-event or survival benefit; different active regimens are not pooled here. Safety, uncertainty, and source detailsGastrointestinal events were most common; adverse events led to discontinuation in both active and placebo groups. Limited to the studied population, formulation and follow-up. Funding/conflicts: Supported by Eli Lilly; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
| TRIUMPH-5 Adults with obesity 800 participants (estimated) Randomized placebo-controlled trial; human | Retatrutide versus Tirzepatide Primary weight endpoint: 80 weeks Primary: Percentage body-weight change Phase: Phase 3 | Active, not recruiting; no registry results posted at the source check. Cannot tell us: A registered head-to-head design is not a completed head-to-head result. Enrollment is estimated. Safety, uncertainty, and source detailsSee primary paper; absence of a signal in this study does not establish general safety. Limited to the studied population, formulation and follow-up. Funding/conflicts: Sponsor: Eli Lilly and Company. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
What did SURMOUNT-1 measure?
A placebo-controlled trial supports weight reduction in the studied adults. The OSA indication has its own label scope.
Limit: This weight trial alone does not establish cardiovascular-event prevention or prove every sleep-apnea indication.
Check the sources: SURMOUNT-1: tirzepatide and obesity (checked 2026-09-18) · FDA Zepbound prescribing information (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Zepbound: Weight management
Subcutaneous injection · Adults with obesity or overweight plus a weight-related condition
approved — Adjunct to reduced-calorie diet and increased physical activity.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Zepbound: Obstructive sleep apnea
Subcutaneous injection · Adults with obesity and moderate-to-severe obstructive sleep apnea
approved — Does not cover every cause or severity of sleep apnea.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Compare research questions · Submit a source-based correction
FDA approval & research status
Tirzepatide products are FDA approved for specific uses, including type 2 diabetes, chronic weight management, and—under the Zepbound label—moderate-to-severe obstructive sleep apnea in adults with obesity.
Approved uses covered here
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults
- Moderate-to-severe obstructive sleep apnea in adults with obesity under the Zepbound label
FDA approved for product-specific uses
Mounjaro and Zepbound have FDA-approved indications, including diabetes, chronic weight management, and the Zepbound obstructive-sleep-apnea indication. The approval does not extend to every metabolic claim.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Outcomes for uses and populations not yet studied in large trials
- Very long-term outcomes across increasingly broad populations
- Whether every ongoing outcome trial will confirm early signals
- Quality and safety of products marketed outside approved supply chains
The takeaway
Tirzepatide has strong evidence for specific approved uses, but brand, indication, eligibility, contraindications, and clinical oversight all matter.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Mounjaro
Official tirzepatide prescribing information for a type 2 diabetes product.
- 2fdaFDA prescribing information: Zepbound
Official tirzepatide prescribing information for chronic weight management and obstructive-sleep-apnea indications.
- 3fdaFDA: first medication approved for obstructive sleep apnea
FDA announcement of the Zepbound obstructive-sleep-apnea indication.
- 4clinical trialsClinicalTrials.gov: SURMOUNT-1 tirzepatide trial
Registry record for a pivotal tirzepatide chronic-weight-management trial.
- 5pubmedSURMOUNT-1 tirzepatide randomized trial
Peer-reviewed report of tirzepatide in adults with obesity.